BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris. The company is also developing BPX02, an injectable product for aesthetic dermatology applications. It serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. The company has collaboration and licensing agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. BioPharmX Corporation is headquartered in Menlo Park, California.